The EndoBarrier Device: A 3-year Follow up Study
The Effect of the EndoBarrier Device: A 3-year Follow up of a Randomized Clinical Trial
Przegląd badań
Szczegółowy opis
In this observational follow-up study of a randomised clinical trial a maximum of 29 study participants may be included. These study participants were previously enrolled in the EndoBarrier device study at the MUMC or the Atrium Medical Centre Heerlen. The focus of this study lays on the long-term outcomes measured by EWL, postoperative blood sampling and questionnaires. These measurements, samples and questionnaires will be taken to assess the long-term effectiveness of the EndoBarrier device in the treatment of morbid obesity. Participants who were previously enrolled in the EndoBarrier device study at the MUMC or at the Atrium Medical Centre in Heerlen and who have agreed to participate in this study will be requested to arrive at the outpatient clinic of the MUMC after an overnight fast. Blood sample will be taken for total cholesterol, HDL, LDL, triglycerides, Hb, Ht, iron, HbA1c, insulin levels, glucose, amylase, lipase, C-peptide, Creatinine, vitamin D, Calcium, ALAT, ASAT, AF, gamma GT, albumin, CK-18, L-FABP, FGF19, Total bile salts and bile salt composition. These parameters are associated with risk factors in morbid obesity namely: Nonalcoholic Fatty Liver disease, hypertension, diabetes mellitus type II (DMII), coronary heart disease and osteoarthritis. After the blood sampling, physical health will be assessed by means of standard physical examination (weight, waist size, length, blood pressure, heart rate, breathing frequency). Then, the participant will be requested to fill in a validated questionnaire. In this study the SF-36 quality of life questionnaire will be used. This is a validated questionnaire assessing non-specific symptoms and quality of life after Bariatric surgery.
Three years of follow-up after the EndoBarrier device is now available. The investigators hope to give new insights in the postoperative status and postoperative symptoms experienced by participants using standardised questionnaires and evaluating blood samples. The goal of the investigators is to study the long-term effect of the EndoBarrier procedure and to possibly provide insight in the relation between success/failure and objective parameters.
Typ studiów
Zapisy (Rzeczywisty)
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Limburg
-
Maastricht, Limburg, Holandia, 6229 HX
- Maastricht University Medical Center
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
Opis
Inclusion Criteria:
- Participants who were previously enrolled in the randomized clinical EndoBarrier procedure trial at the MUMC and the Atrium Medical Centre Heerlen regardless of their excess weight loss.
- Participants who have a follow up of at least 3 years.
- Signed informed consent.
Exclusion Criteria:
- Post-EndoBarrier conventional bariatric surgery
- Participants who were lost to follow-up during the previous conducted EndoBarrier clinical trial.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
Kohorty i interwencje
Grupa / Kohorta |
Interwencja / Leczenie |
|---|---|
|
EndoBarrier
Participants who were previously enrolled in the randomized clinical EndoBarrier procedure trial at the MUMC and the Atrium Medical Centre Heerlen.
|
The device is a 60-cm long, impermeable plastic sleeve that is open at both sides so food can pass through.
The sleeve is anchored in the duodenal bulb and extends partially into the jejunum.
This way the pancreatic and bile juices will only mix with the food after the sleeve, hereby creating a functional bypass of the duodenum and the proximal jejunum, which causes malabsorption of nutrients.
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Ramy czasowe |
|---|---|
|
Excess Weight (%)
Ramy czasowe: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Insulin levels (mmol/L)
Ramy czasowe: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
|
|
Total Cholesterol (mmol/L)
Ramy czasowe: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
|
|
SF-36 health related quality of life, patient-reported survey of patient health
Ramy czasowe: 36 months post explant EndoBarrier Liner
|
The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section.
Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight.
The lower the score the more disability.
|
36 months post explant EndoBarrier Liner
|
|
FGF 19 (ng/ml)
Ramy czasowe: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
|
|
ASAT (U/L)
Ramy czasowe: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
|
|
Amylase (U/L)
Ramy czasowe: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
|
|
Systolic blood pressure (mmHg)
Ramy czasowe: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
|
|
BMI (Kg/M2)
Ramy czasowe: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
|
|
Diastolic blood pressure (mmHg)
Ramy czasowe: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
|
|
glucose levels (mmol/L)
Ramy czasowe: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
|
|
HbA1c level (%)
Ramy czasowe: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
|
|
Triglycerides (mmol/L)
Ramy czasowe: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
|
|
HDL (mmol/L)
Ramy czasowe: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
|
|
LDL (mmol/L)
Ramy czasowe: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
|
|
L-FABP (ng/ml)
Ramy czasowe: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
|
|
Lipase (U/L)
Ramy czasowe: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
|
|
ALAT (U/L)
Ramy czasowe: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
|
|
AF (U/L)
Ramy czasowe: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
|
|
GammaGT (U/L)
Ramy czasowe: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
|
|
Albumin (g/L)
Ramy czasowe: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
|
|
CK-18 (U/L)
Ramy czasowe: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
|
|
C-peptide (nmol/L)
Ramy czasowe: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
Współpracownicy i badacze
Śledczy
- Główny śledczy: Nicole Bouvy, MD, PhD, Maastricht University Medical Center, The Netherlands
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Inne numery identyfikacyjne badania
- NL51074.068.14
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .